In the world of clinical trials, not all research is created equal. While many studies aim to answer pressing scientific questions, others may prioritize marketing goals. Recent research, analyzing over 34,000 industry-backed trials, suggests that certain studies across diverse medical fields might be crafted more for promoting drugs to doctors than for advancing scientific understanding. In some medical areas, nearly 1% of these trials might have marketing at their core.
These trials, known as seeding trials, operate under the guise of legitimate research but primarily aim to market new drugs to physicians. Although they appear scientific, their true objective is to familiarize doctors with a drug, often without generating substantial scientific data. Physicians involved in these trials might believe they are contributing to medical knowledge, while in reality, the risks borne by patients serve corporate rather than scientific interests.
The term “seeding trial” was first introduced in the medical literature in 1994 when David Kessler, then-commissioner of the Food and Drug Administration, described these studies as attempts to entice doctors into prescribing new drugs under the pretense of scientific research. Despite the passing of three decades, the issue of seeding trials remains a concern.
Understanding Seeding Trials
At first glance, seeding trials appear similar to traditional clinical trials, but their goals starkly differ. In a standard clinical trial, the focus is on determining the safety and efficacy of a treatment. Conversely, seeding trials are structured to reach a broad number of physicians, enrolling them based on their prescribing habits rather than research expertise, with an emphasis on increasing drug prescriptions.
Seeding trials frequently target drugs already on the market, often in Phase 4, or postmarketing, studies. These studies usually receive less regulatory oversight and may focus on less clinically relevant endpoints, such as patient preferences or drug dissolution rates, rather than health outcomes.
Unlike genuine trials with independent oversight, seeding trials often have minimal external review. The pharmaceutical sponsors maintain significant control over study design and execution, raising ethical concerns about patient safety and research integrity.
Notable Cases of Seeding Trials
Seeding trials gained public attention primarily through legal actions in the 1990s, which unveiled internal documents from pharmaceutical companies. The Merck ADVANTAGE trial for Vioxx and Parke-Davis’ STEPS trial for Neurontin are prominent examples where marketing was disguised as research. These revelations highlighted the trials’ intentions to promote drug prescriptions, with significant legal and financial repercussions following Vioxx’s market withdrawal.
Prevalence and Identification of Seeding Trials
Research efforts have attempted to quantify the prevalence of seeding trials. By examining nearly 34,400 industry-funded Phase 3 and Phase 4 studies, researchers identified 204 trials with characteristics suggestive of marketing motives. However, definitive identification of seeding trials requires access to internal documents, often only available through litigation.
Catherine McQueen/Moment via Getty Images
While some trials might generate valuable data, they can still serve promotional goals. The true scope of marketing-driven research remains uncertain without systematic surveillance and access to internal company documents.
Addressing the Issue
To ensure clinical research serves patients, transparency in trial registration and funding disclosure is essential. Proposed reforms include standardized reporting and independent oversight to monitor trial conduct. The U.S. Open Payments database facilitates public tracking of industry payments to physicians, but regulatory differences across countries can impact the oversight of marketing-driven trials.
Clinicians can protect their practice by recognizing red flags, such as low patient-to-site ratios and sponsor-dominated oversight, before engaging with a trial. Clearer disclosure of a study’s commercial and scientific objectives is among the recommended reforms. Ultimately, the crucial question remains: Who truly benefits from a clinical trial?
